58957-92-9 (伊达比星,Idarubicin)

伊达比星;依达比星;4-去甲氧基柔红霉素;伊达吡星;(1S,3S)-3-乙酰-1,2,3,4,6,11-六氢-3,15,12-三羟基-6,11-二氧代-L-丁炔基-3-氨基-2,3,6-三脱氧基-Α-L-来苏糖吡喃己糖苷;盐酸伊达比星;盐酸伊达比星 Idarubicin HCl;

Idarubicin;(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;4-demethoxydaunomycin;4-Demethoxydaunorubicin;5,12-naphthacenedione;Idamycin;Idarubicina;Idarubicine;Idarubicine [INN-French];Idarubicinum;Idarubicinum [INN-Latin];5,12-Naphthacenedione,9-acetyl-7-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-,(7S-cis)-;1-Demethoxydaunorubicin;4-DMD;Demethoxydaunorubicin;SR-01000075934;IDARUBICIN [WHO-DD];SMR000466355;(7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-9-ethanoyl-6,9,11-tris(oxidanyl)-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride;(7S,9S)-9-Acetyl-7-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione;BCP9000773;4-Desmethoxydaunorubicin;(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;Daunomycin, 4-demethoxy-;NCGC00093976-03;AB00698511-08;SDCCGSBI-0050582.P002;HY-17381A;SR-01000075934-1;4-DEMETHOXY-DAUNORUBICIN;NCGC00093976-02;DTXSID7023142;Tox21_500600;IDARUBICIN [VANDF];AKOS015895563;5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)-;UNII-ZRP63D75JW;MLS001401448;Lopac0_000600;NSC256439;Idarubicinum (INN-Latin);DTXCID503142;(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride;5,12-Naphthacenedione, 7,8,9,10-tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-, (7S-cis)-;AB00698511-09;NCGC00093976-18;A935911;(1S,3S)-3-ACETYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSIDE;58957-92-9;(1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-hexopyranoside;GTPL7083;(7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-9-ethanoyl-6,9,11-tris(oxidanyl)-8,10-dihydro-7H-tetracene-5,12-dione;AB00698511_11;Idarubicine (INN-French);(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-quinone;hydrochloride;L01DB06;EN300-7479233;DB01177;CS-0007534;(7S,9S)-9-acetyl-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;Idarubicin, United States Pharmacopeia (USP) Reference Standard;D08062;A832088;AB00698511-06;Zavedos (TN);XDXDZDZNSLXDNA-TZNDIEGXSA-N;EU-0100600;HMS2089D05;NCGC00261285-01;(7S,9S)-9-acetyl-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride;IDARUBICIN [MI];BCPP000207;NCGC00093976-01;NCGC00093976-05;BRD-K69650333-001-01-1;Idarubicin (INN);CHEMBL1117;5,12-NAPHTHACENEDIONE, 9-ACETYL-7-((3-AMINO-2,3,6-TRIDEOXY-alpha-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,9,11-TRIHYDROXY-, (7S,9S)-;AC-9384;Idarubicina [INN-Spanish];NSC 256439;(1S,3S)-3-ACETYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-alpha-L-LYXO-HEXOPYRANOSIDE;cid_636362;ZRP63D75JW;(7S,9S)-9-acetyl-7-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,9,11-trihydroxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione;(7S,9S)-9-acetyl-7-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione;DM5;4 Desmethoxydaunorubicin;(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside;Idarubicin [INN:BAN];Q1063862;Idarubicin hydrochloride, solid;CCG-204689;CCRIS 5083;BRD-K69650333-001-02-9;CHEBI:42068;NCGC00093976-04;5,12-Naphthacenedione, 7,8,9,10-tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-, (7S-cis)-;HMS3261H22;4 Demethoxydaunorubicin;Idarubicina (INN-Spanish);5,12-NAPHTHACENEDIONE, 9-ACETYL-7-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,9,11-TRIHYDROXY-, (7S,9S)-;4-DMDR;(7S-cis)-9-Acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione;(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside;Idarubicinhydrochloride;BDBM58490;I 1656;LP00600;AB00698511-10;KBioSS_002388;BRD-K69650333-003-14-0;SCHEMBL3750;IDARUBICIN [INN];NCGC00093976-12;5,12-Naphthacenedione,9-acetyl-7-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S,9S)-;BRD-K69650333-003-13-2;Idarubicin?;

MFCD00897212

XDXDZDZNSLXDNA-TZNDIEGXSA-N

1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1

O([C@H]1C[C@@H]([C@@H]([C@H](C)O1)O)N)[C@@H]1C2C(=C3C(C4C=CC=CC=4C(C3=C(C=2C[C@@](C(C)=O)(C1)O)O)=O)=O)O

260-990-7

抗肿瘤药。

-40℃和氩气保护下，将化合物((-)-Ⅱ)(159mg，0.29mmo1)和0.8g4A分子筛悬浮于12ml二氯甲烷和10ml乙醚的混合液中，加入TMSOTf(0.12ml，0.62mmo1)。在0℃下搅拌1h。冷却至-15℃，加入化合物(+)-(I)(85mg，0.23mm...